Fennec Pharmaceuticals (FRX) Stock Overview
Operates as a commercial stage biopharmaceutical company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
FRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Fennec Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.50 |
| 52 Week High | US$13.83 |
| 52 Week Low | US$7.02 |
| Beta | 0.78 |
| 1 Month Change | 0.29% |
| 3 Month Change | -9.40% |
| 1 Year Change | 26.51% |
| 3 Year Change | -21.70% |
| 5 Year Change | 6.06% |
| Change since IPO | -97.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| FRX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 3.3% | 2.4% | 2.3% |
| 1Y | 26.5% | 26.9% | 31.0% |
Return vs Industry: FRX exceeded the Canadian Biotechs industry which returned 20.6% over the past year.
Return vs Market: FRX underperformed the Canadian Market which returned 31.3% over the past year.
Price Volatility
| FRX volatility | |
|---|---|
| FRX Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 10.2% |
| 10% most volatile stocks in CA Market | 19.5% |
| 10% least volatile stocks in CA Market | 3.3% |
Stable Share Price: FRX has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: FRX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 32 | Jeff Hackman | fennecpharma.com |
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Fennec Pharmaceuticals Inc. Fundamentals Summary
| FRX fundamental statistics | |
|---|---|
| Market cap | CA$359.80m |
| Earnings (TTM) | -CA$9.64m |
| Revenue (TTM) | CA$53.91m |
Is FRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRX income statement (TTM) | |
|---|---|
| Revenue | US$38.79m |
| Cost of Revenue | US$2.67m |
| Gross Profit | US$36.12m |
| Other Expenses | US$43.06m |
| Earnings | -US$6.94m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 93.12% |
| Net Profit Margin | -17.89% |
| Debt/Equity Ratio | -431.4% |
How did FRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/15 19:50 |
| End of Day Share Price | 2026/01/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fennec Pharmaceuticals Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Naureen Quibria | Capital One Securities, Inc. |
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |